Acorda Therapeutics

#8700

Rank

$821.03K

Marketcap

United States

Country

Leadership team

Dr. Ron Cohen M.D. (Founder, CEO, Pres & Director)

Dr. Burkhard Blank M.D. (Interim Head of Drug Safety)

Mr. Michael A. Gesser M.B.A. (Chief Financial Officer)

Products/ Services

Biotechnology, Developer Platform, Health Care

Number of Employees

100 - 500

Headquarters

Hawthorne, New York, United States

Established

1995

Company Registration

SEC CIK number: 0001008848

Revenue

100M - 500M

Traded as

ACOR

Social Media

URL

https://www.acorda.com

Overview

Location

Recognition and Award

References

Summary

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

History

Acorda Therapeutics is a pharmaceutical company that was founded in 1995. The company is dedicated to developing novel therapies that restore and reverse neurological deficits, improve coordination and functioning, and reduce pain. Acorda has reached success with proprietary treatments for multiple sclerosis that are taken orally and provide greater efficacy to patients than previous therapies.

Mission

Acorda’s mission is to develop therapies that restore function and improve the lives of people with neurological disorders.

Vision

Bringing hope to people with neurological disorders by creating life-changing therapies that deliver meaningful clinical benefit to address unmet medical needs.

Key Team

Mr. Robert Morales (Interim Principal Accounting Officer, Principal Financial Officer, VP of Fin. & Controller)

Ms. Tierney Saccavino (Exec. VP of Corp. Communications)

Ms. Felicia Vonella (VP of Investor Relations)

Mr. Neil S. Belloff Esq. (Gen. Counsel & Corp. Sec.)

Mr. Andrew Mayer J.D. (Sr. VP)

Ms. Denise J. Duca (Exec. VP of HR)

Mr. Kerry M. Clem (Chief Commercial Officer)

Recognition and Awards

Acorda Therapeutics has received numerous awards and recognitions, including the Global Life Sciences & Innovation Outstanding Employer Award, the Golden Triangle of Tampa Bay – Top Employer Award, and the Channel Islands Life Sciences Employer of the Year Award.